2014
Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2
Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal Of Korean Medical Science 2014, 29: 351-356. PMID: 24616583, PMCID: PMC3945129, DOI: 10.3346/jkms.2014.29.3.351.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkersCarrier ProteinsEndopeptidasesFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedMuscle NeoplasmsNeoplasm InvasivenessNeoplasm StagingPlatelet Glycoprotein GPIb-IX ComplexPredictive Value of TestsRegression AnalysisRisk FactorsROC CurveUbiquitin ThiolesteraseUrinary Bladder NeoplasmsConceptsCancer-specific survivalCancer-specific deathBladder cancer patientsHigh expression groupExpression of USP18MIBC patientsCancer patientsExpression groupMuscle-invasive bladder cancer patientsCancer-specific survival ratesInvasive bladder cancer patientsMuscle-invasive bladder cancerLonger cancer-specific survivalMultivariate Cox regression analysisCox regression analysisInvasive bladder cancerSignificant risk factorsReliable prognostic markersMRNA expression levelsSurvival-related genesOverall survivalValidation cohortOriginal cohortLonger survivalPredicting Survival
2013
Active surveillance in men with low-risk prostate cancer: current and future challenges.
Han C, Parihar J, Kim I. Active surveillance in men with low-risk prostate cancer: current and future challenges. American Journal Of Clinical And Experimental Urology 2013, 1: 72-82. PMID: 25374902, PMCID: PMC4219278.Peer-Reviewed Original ResearchLow-risk prostate cancerActive surveillanceProstate cancerSurvival rateCancer-specific survival ratesProstate-specific antigen (PSA) screeningActive surveillance protocolsCost of overtreatmentActive surveillance programPSA kineticsAntigen screeningSurveillance protocolInstitutional protocolEligibility criteriaMortality rateNew biomarkersCancerSurveillance programLong-term studiesTreatment triggersInterventionMenGenetic testsSurveillanceContemporary review